ReviewFrontiers in immunology2026
MicroRNAs in immune-related diseases: mechanism, functions and therapeutic perspectives.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MicroRNAs (miRNAs) are evolutionarily conserved, non-coding RNA molecules approximately 18-25 nucleotides in length that regulate gene expression at the post-transcriptional level. Their principal mechanism of action is post-transcriptional gene silencing via RNA interference, achieved by binding to complementary sequences within target messenger RNAs (mRNAs). Accumulating evidence has highlighted the pivotal role of miRNAs in the development, differentiation, and function of immune cells, as well as in maintaining immune homeostasis. A more comprehensive understanding of the complex molecular networks governed by these miRNAs may provide valuable insights into disease mechanisms, facilitate clinical decision-making, and ultimately improve patient outcomes. The remarkable stability of miRNAs, together with their presence in the systemic circulation encapsulated within extracellular vesicles, has attracted considerable interest in their clinical application. These characteristics make circulating miRNAs promising candidates as diagnostic biomarkers for the early detection of disease and as prognostic indicators for disease progression and evaluating therapeutic efficacy. Furthermore, an increasing number of miRNA-based studies across diverse immune-related disorders have revealed their potential as therapeutic targets. The integration of synergistic therapeutic strategies and complementary miRNA-based approaches may further enhance treatment efficacy and contribute to the development of novel precision-medicine interventions for immune-related diseases. In this review, we comprehensively discuss the biogenesis and biological functions of miRNAs and examine their regulatory roles in the pathogenesis of rheumatoid arthritis (RA), inflammatory bowel disease (IBD), multiple sclerosis (MS), psoriasis, systemic lupus erythematosus (SLE), and atopic dermatitis (AD). We are also evaluating the potential of these miRNAs as diagnostic and prognostic biomarkers, and their promising properties as therapeutic targets in the treatment of immune system-related diseases. These selected diseases represent key immune disorders in which miRNAs serve as strong biomarker candidates for early diagnosis (diagnostic) and disease course (prognostic) due to their stability in systemic circulation and their presence within extracellular vesicles. These six diseases constitute the cluster of "immune-related disorders," where miRNA-based studies are steadily increasing, and these molecules hold the highest potential as novel therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.